Valink Therapeutics
Develops bispecific antibody-drug conjugate cancer candidates and offers collaboration on its discovery platform to biopharma partners
Highlights
- New on EvolcAdded 2026-11-13
About Valink Therapeutics
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for cancer, designed to attack tumour cells more selectively while sparing healthy tissue. Its proprietary LiliumX discovery platform combines synthetic protein biology, high-throughput functional screening and AI, and its V-Gate approach tunes binding to continuous levels of two cell-surface targets.
The company advances three oncology-focused programs and invites collaboration on its discovery engine. It closed an $11.8 million pre-A financing round in October 2025 and announced a strategic alliance with Nona Biosciences in December 2025.
Valink was founded in 2020 and is headquartered in London, United Kingdom, at Imperial I-Hub. It also lists an office in Cambridge, Massachusetts, United States. Its leadership includes co-founders Arne Scheu (CEO) and Irsyad Khairil (CTO), and its board is chaired by Martin D. Williams.
Product: Bispecific antibody-drug conjugate drug candidates for oncology, discovered with the LiliumX platform and V-Gate approach.
Jobs at Valink Therapeutics
Leadership
- Arne Scheu · Co-Founder & CEOSource: company website
- Irsyad Khairil · Co-Founder & CTOSource: company website
More biotech & pharma companies
Valneva UK
Develops and supplies travel vaccines and clinic support for healthcare providersVector Futures
AI-guided genetic engineering and contract research for biological product developersYoung companyNew on EvolcVedaly
AI research platform and data consulting for biopharma R&D and translational teamsYoung companyNew on EvolcVerdiva Bio
Develops once-weekly peptide medicines for obesity and cardiometabolic disease, with a lead drug in Phase 2 trialsYoung companyVernalis (R&D)
Drug discovery research and development services for pharmaceutical and biotechnology partnersViramal
Develops women's health medicines and therapies for sexual, vaginal and reproductive conditionsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.